Irish pharmaceutical company Solvotrin Therapeutics is developing a range of Aspirin prodrugs that could be used in the fight against cancer, following study results published in the Lancet medical journal.
A new study backs the role of Aspirin in the prevention of cancer and in particular, colorectal cancer. These study results are consistent with the results of previous studies, where Aspirin was found to reduce the risk of death from several cancers, including breast cancer (by up to 70pc), and lung cancer (by up to 30pc).
“The CAPP2 clinical study clearly demonstrates that Aspirin can prevent cancer. However, the beneficial effects of Aspirin only became apparent following long-term use of at least three to four years and at high doses (600mg) of Aspirin,” said Pat O’Flynn, CEO of Solvotrin Therapeutics. Dr John Gilmer and his team in the School of Pharmacy and Pharmaceutical Sciences in Trinity College Dublin discovered the range of Aspirin prodrugs Solvotrin Therapeutics is now developing. “While traditional Aspirin can cause gastrointestinal damage, bleeding and ulcers, even at low doses, Solvotrin’s prodrugs do not cause injury to the stomach and intestines, and there is enormous